Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 2/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30406782 | 0.98 | EGFR (0.62) | EGFRALDH1A1GLAF2HPGD | |
| Hydrochloric Acid SCHEMBL27748921 | 0.98 | EGFR (0.62) | EGFRALDH1A1GLAF2HPGD | |
| SCHEMBL27881436 | 0.98 | EGFR (0.62) | EGFRALDH1A1GLAF2HPGD | |
| SCHEMBL5144896 | 0.92 | EGFR (0.55) | EGFRALDH1A1GLAF2HPGD | |
| SCHEMBL3942891 | 0.89 | EGFR (0.61) | EGFRALDH1A1GLAF2HPGD | |
| SCHEMBL27630991 | 0.88 | EGFR (0.64) | EGFRALDH1A1GLAF2HPGD | |
| SCHEMBL13480994 | 0.84 | EGFR (0.59) | EGFRALDH1A1GLAF2HPGD | |
| SCHEMBL27685719 | 0.82 | EGFR (0.56) | EGFRALDH1A1GLAF2HPGD | |
| SCHEMBL30648200 | 0.80 | KMT2A (0.59) | EGFRALDH1A1CA2CA12CA9 | |
| SCHEMBL27651503 | 0.80 | KMT2A (0.59) | EGFRALDH1A1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | claimed |
| EP-1633365-B1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-08 | — | — | EP | claimed |
| EP-2305687-A1 | Quinazoline derivatives | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | claimed |
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | claimed |
| JP-2007504276-A | — | — | 2007-03-01 | — | — | JP | claimed |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | claimed |
| EP-1633365-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | claimed |
| WO-2004105765-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | claimed |
| WO-2025063725-A1 | NOVEL SKELETAL DERIVATIVE EFFECTIVE FOR HER2 MUTATION, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 한미약품 주식회사 | 2025-03-27 | — | — | WO | disclosed |
| CN-104744446-B | Heteroaryl compound and its application in drug | 广东东阳光药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-104098551-B | Substituted quinazoline analog derivative as Ou Ruola kinase inhibitor | 广东东阳光药业有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-108341813-A | Substituted 1- (isoxazole -3- bases) -3- (the fluoro- 4- phenyl of 3-) urea derivative and its preparation method and application | 四川大学 | 2018-07-31 | — | — | CN | disclosed |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| CN-102718775-B | As the Macrocyclic quinazoline derivatives of antiproliferative | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-02-17 | — | — | CN | disclosed |
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | disclosed |
| US-7648975-B2 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
| CN-101535279-A | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| EP-1633365-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105765-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | NR1H3, NR1H2, NCOA3 | EGFR 684/4885ALDH1A1 2648/4885GLA 4507/4885 |
| US-20100105668-A1 | Quinazoline derivatives | NR1H2, NR1H3, NR3C2 | EGFR 1789/4885ALDH1A1 2784/4885GLA 4418/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | EGFR 1503/4885ALDH1A1 2932/4885GLA 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.